Duke University

The University of North Carolina at Chapel Hill

Kouros Owzar

Mark W Dewhirst

Sharareh Reihani

Chen Jiang

Herbert I Hurwitz

Mark D Starr

Andrew B Nixon

Oana I Craciunescu

Jin Wang

Julia Quintanilha

Angeles Alvarez Secord

Chris Brady

Yingmiao Liu

Federico Innocenti

Danyu Lin

Alexander Sibley

Ace Hatch

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.

Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer

The disclosure relates to methods of identifying subjects at risk of developing bevacizumab-induced toxicities such as proteinuria and/or hypertension involving measuring nucleic acid or gene mutations in a sample obtained from the subject.

Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension

The present disclosure provides methods and kits for using biomarkers for predicting treatment response, determining likely survival rate, and/or determining aggressiveness of conditions such as Locally Advanced Breast Cancer (LABC) and Inflammatory Breast Cancer (IBC) in a subject.

Biomarkers for locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC)

The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serous carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC.

Biomarkers of high-grade serous ovarian carcinomas

Growing community of inventors

Durham, NC, United States of America

Kouros Owzar